Joint Programming Initiative on Antimicrobial Resistance

Stakeholder involvement and extension of partnerships


The overall objective of this WP is to develop and implement a strategy to ensure European-wide stakeholder
engagement with the JPIAMR. Stakeholders will include representatives from industry (pharmaceutical,
diagnostic and medical devices), SMEs, public health authorities, professional and patient organisations, centres for disease prevention and control, hospital associations, NGOs and policy makers. The WP will also identify how the JPIAMR can work in partnership with other initiatives at the European and global level. Several actions will be taken:

  • Establishing a Stakeholder Advisory Board
  • Developing ways of interacting with the most representative bodies involved in AMR topics (e.g. ECDC, WHO, EMA)
  • Identifying and implementing ways in which the JPIAMR can actively engage with stakeholders, and specifically with industry.
  • Extending the partnership by creating synergies between JPIAMR and other global organisations and initiatives.

Description of work and role of partners

The emergence of AMR is a problem which spans many different fields of society. Therefore stakeholder
involvement in the process of identifying how the European research effort can be most effectively harnessed to address the problem is highly important. Communication with stakeholders is also important to raise awareness of the importance of the JPI across the EU. A strategy for establishing methods to provide information on the JPIAMR and its activities to specific stakeholders will be developed in collaboration with WP2 (Task 2.1). Stakeholders can provide input into the Strategic Research Agenda from a user and societal perspective and help define urgent R&D needs. Their involvement in the development of the SRA, its implementation, and the JPIAMR as a whole, is likely to bring research outcomes closer to implementation and enhance the social value of the research initiatives and the joint programming. Therefore, WP5 will work in close connection to WP3 and WP4.

Task 5.1: Establishing the Stakeholder Advisory Board (SHAB) (M1 to M6)
(Task leader: NASR)

As defined in the JPIAMR Terms of Reference, a Stakeholder Advisory Board (SHAB) will be established at the
beginning of the CSA period. The role of the SHAB will be to provide a societal perspective on the issues raised by the JPI and to provide advice on JPIAMR activities to the Science Advisory Board, WPs and Management Board. SAB and MB will nominate members for the SHAB and the formal decision on which to include will be made by the MB. The composition of the SHAB will also influence the communication strategy developed in WP2. The SHAB is envisaged to include representatives from EU-wide professional organisations, public health authorities, professional and patient organisations, NGOs, centres for disease prevention and control, hospital associations and policy makers. Examples of possible organisations to include; ReAct, IMI, EFPIA, EMA, WHO and Médecins Sans Frontières. Single companies with interests in the AMR sector will not be included in the SHAB, but will be approached in task 5.3 below. The SHAB will meet at least once a year, members will be invited to relevant workshops held by JPI WPs and will be consulted electronically as required.

Task 5.2 Developing ways of working with stakeholders (M4 to M12)
(Task leader: NASR Contributors: ZonMw, JÜLICH)

This task will develop ways in which the JPIAMR will engage with stakeholders identified in task 5.1. The
most appropriate and efficient approaches for engagement will be identified (e.g., by using questionnaires,
benchmarking with relevant initiatives) in consultation with SHAB, SAB and MB members and a plan for
engagement with the different groups will be developed (what, how, when) and updated annually. In addition,
WP participants will form wider networks with stakeholder groups as the basis for long term interaction and
establish a forum for two way communication, knowledge exchange and cooperation with the groups and the
participating member states. In partnership with WP3 and WP4, this task will additionally establish and develop the methods for how the SHAB, and wider stakeholders, can feed into the development of the SRA (WP3) and its implementation (WP4). The results of the task will be presented to the MB as an outline of actions.

Task 5.3 Industrial cooperation (M1 to M36) (Task leader: NASR, Contributors: MRC)

Building on the industry contacts workgroup already established by the Management Board, this task will
be specifically aimed at industry engagement with the JPIAMR. Whilst engagement with all stakeholders
identified in tasks 5.1 and 5.2 will be vital for the success of the JPIAMR, there is a particular need for targeted cooperation with industry; including the pharmaceutical, diagnostic and medical devices industries and SMEs. New antibiotics are urgently required but a lack of a robust pipeline illustrates the problems of antibacterial drug discovery and development.

A forum for knowledge exchange with industry will be established. This will provide a platform for two-way
information exchange and communication which will shape the development and implementation of the SRA
and subsequent JPI activities. In conjunction with WP3 and WP4, a series of meetings will be held with SAB
members, representatives from EU-wide professional organisations (e.g. EFPIA), IMI and companies to identify scientific challenges and opportunities for joint working and future engagement. Examples of possible topics to address; identifying and addressing obstacles in the research and innovation system that prevent innovative solutions; cooperation framework (scientific, financial, legal and ethical aspects); communication /networking strategy (exchanging information, methodologies and guidelines in AMR).

Task 5.4 Exploring synergies between JPIAMR and other global initiatives (M1 to M36)
(Task leader: NASR; Contributors: ANR)

Antibiotic resistance is a global problem and in this task the JPIAMR will explore synergies between work of the JPI and international organisations e.g., WHO, global policy makers and funders, and on-going global initiatives in this field, e.g. the EU-US Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) in collaboration with ECDC, and ReAct – Action on Antimicrobial Resistance. A paper outlining the options on the possible synergies between JPIAMR and international organisations will be delivered to the MB. The task will provide options to MB for collaboration and knowledge sharing, linking with initiatives outside Europe.